{"id":"W4387810529","doi":"10.1016/j.annonc.2023.09.2538","title":"1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada)","funders":"Daiichi-Sankyo; Daiichi Sankyo Europe; AstraZeneca","keywords":"Medicine; Internal medicine; Oncology; Pemetrexed; Carboplatin; Chemotherapy; Combination therapy; Phases of clinical research; non-small cell lung cancer (NSCLC); Lung cancer; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001419711,0.001104066,0.001842793,0.0004212224,0.0003722463,0.001090016,0.0009135986,0.001118312,0.004473813],"category_scores_gemma":[0.0006984952,0.0004845035,0.001221092,0.0004414725,0.0009816305,0.0006787792,0.0003708129,0.002356488,0.0009088563],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009474714,"about_ca_system_score_gemma":0.001855152,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002272068,"about_ca_topic_score_gemma":0.005618275,"domain_scores_codex":[0.9995944,0.0001931637,0.0000169965,0.00006026413,0.00002370556,0.0001113953],"domain_scores_gemma":[0.9993979,0.00009467432,0.00007142127,0.00004539531,0.00002695178,0.0003638057],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8757684,0.04460292,0.006948449,0.0002398545,0.0009849927,0.0001205743,0.0001401546,0.001267962,0.0192228,0.0002227672,0.002060242,0.04842085],"study_design_scores_gemma":[0.569793,0.4115562,0.01314931,0.00002044524,0.0005290183,0.0001192464,0.00005489394,0.0007839567,0.002139738,0.00009461414,0.001740291,0.00001927841],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995352,0.0009814594,0.0001980423,0.0002948787,0.0001196614,0.0008952743,0.0008618337,0.00004766123,0.001249239],"genre_scores_gemma":[0.9906583,0.001210516,0.0008171792,0.0006097296,0.0002045549,0.001086018,0.00271409,0.00002685444,0.002672795],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004473813,"threshold_uncertainty_score":0.01496637,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08150752208758626,"score_gpt":0.4458721133865545,"score_spread":0.3643645912989683,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}